RxDoctor Payments Data

Alpesh Amin, MD

Advanced Heart Failure and Transplant Cardiology · Fort Worth, TXNPI 1760440192

Payments from drug & device makers

$3,362in general payments, 2019–2025

Across 52 payments — averaging $64.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$2K
  • Abbott$547
  • Getinge USA Sales, LLC$495
  • E.r. Squibb & Sons, L.L.C.$142
  • Pfizer$64
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$40
  • plus $36 from 2 others

What the payments were for

  • Travel & lodging$1,40942%
  • Food & beverage$1,95358%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,362 in reported general payments places this provider in the 15th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.

See all advanced heart failure and transplant cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$93,676
Medicare patients
274
Services billed
996

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis30$665,136
VyndaqelTafamidis Meglumine17$362,060
EntrestoSacubitril/Valsartan121$110,503
JardianceEmpagliflozin110$101,184
EliquisApixaban48$45,886
FarxigaDapagliflozin Propanediol30$19,338
Repatha SureclickEvolocumab18$9,578
Metoprolol Succinate156$3,029
Spironolactone191$1,596
Losartan Potassium118$1,154
Torsemide38$922
Amiodarone Hcl53$846
Potassium Chloride33$737
Carvedilol75$688
Lisinopril44$419

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Vyndaqel, Eliquis$64$1,073,08395 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.

Other advanced heart failure and transplant cardiology in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →